Advanced search
Publication Cover
Expert Review of Neurotherapeutics Volume 11, 2011 - Issue 9
Submit an article Journal homepage
143
Views
13
CrossRef citations to date
0
Altmetric
Theme: Demyelinating diseases - Review

Antiganglioside antibodies in Guillain–Barré syndrome and its related conditions

Nortina Shahrizaila Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia; Division of Neurology, Department of Medicine, Faculty of Medicine, University of Malaya, Malaysia
&
Nobuhiro Yuki Department of Microbiology, National University of Singapore, 5 Science Drive 2, Block MD4A, Level 5, Singapore 117597, Singapore;[email protected]
Pages 1305-1313 | Published online: 09 Jan 2014

References

  • Guillain G, Barré JA, Strohl A. [Radiculoneuritis syndrome with hyperalbuminosis of cerebrospinal fluid without cellular reaction. Notes on clinical features and graphs of tendon reflexes]. Bulletins et mémoires de la Société des Médecins des Hôpitaux de Paris40, 1462–1470 (1916).
  • McKhann GM, Cornblath DR, Griffin JW et al. Acute motor axonal neuropathy: a frequent cause of acute flaccid paralysis in China. Ann. Neurol.33(4), 333–342 (1993).
  • Fisher M. An unusual variant of acute idiopathic polyneuritis (syndrome of ophthalmoplegia, ataxia and areflexia). N. Engl. J. Med.255(2), 57–65 (1956).
  • Mori M, Kuwabara S, Fukutake T, Yuki N, Hattori T. Clinical features and prognosis of Miller Fisher syndrome. Neurology56(8), 1104–1106 (2001).
  • Yuki N. Ganglioside mimicry and peripheral nerve disease. Muscle Nerve35(6), 691–711 (2007).
  • Ilyas AA, Willison HJ, Quarles RH et al. Serum antibodies to gangliosides in Guillain–Barré syndrome. Ann. Neurol.23(5), 440–447 (1988).
  • Hadden RDM, Cornblath DR, Hughes RAC et al. Electrophysiological classification of Guillain–Barré syndrome: clinical associations and outcome. Ann. Neurol.44(5), 780–788 (1998).
  • Jacobs BC, van Doorn PA, Schmitz PIM et al.Campylobacter jejuni infections and anti-GM1 antibodies in Guillain–Barré syndrome. Ann. Neurol.40(2), 181–187 (1996).
  • Rees JH, Gregson NA, Hughes RAC. Anti-ganglioside GM1 antibodies in Guillain–Barré syndrome and their relationship to Campylobacter jejuni infection. Ann. Neurol.38(5), 809–816 (1995).
  • Hiraga A, Mori M, Ogawara K, Hattori T, Kuwabara S. Differences in patterns of progression in demyelinating and axonal Guillain–Barré syndromes. Neurology61(4), 471–474 (2003).
  • Kokubun N, Nishibayashi M, Uncini A, Odaka M, Hirata K, Yuki N. Conduction block in acute motor axonal neuropathy. Brain133(Pt 10), 2897–2908 (2010).
  • Ropper AH. Further regional variants of acute immune polyneuropathy: bifacial weakness or sixth nerve paresis with paresthesias, lumbar polyradiculopathy, and ataxia with pharyngeal–cervical–brachial weakness. Arch. Neurol.51(7), 671–675 (1994).
  • Hiraga A, Mori M, Ogawara K et al. Recovery patterns and long term prognosis for axonal Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry76(5), 719–722 (2005).
  • Asahina M, Kuwabara S, Suzuki A, Hattori T. Autonomic function in demyelinating and axonal subtypes of Guillain–Barré syndrome. Acta Neurol. Scand.105(1), 44–50 (2002).
  • Albers JW, Donofrio PD, McGonagle TK. Sequential electrodiagnostic abnormalities in acute inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve8(6), 528–539 (1985).
  • Asbury AK, McKhann GM. Changing views of Guillain–Barré syndrome. Ann. Neurol.41(3), 287–288 (1997).
  • Hafer-Macko CE, Sheikh KA, Li CY et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann. Neurol.39(5), 625–635 (1996).
  • Kusunoki S, Chiba A, Hitoshi S, Takizawa H, Kanazawa I. Anti-Gal-C antibody in autoimmune neuropathies subsequent to mycoplasma infection. Muscle Nerve18(4), 409–413 (1995).
  • Ilyas AA, Mithen FA, Dalakas MC, Chen ZW, Cook SD. Antibodies to acidic glycolipids in Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neurol. Sci.107(1), 111–121 (1992).
  • Susuki K, Yuki N, Hirata K, Kuwabara S. Fine specificities of anti-LM1 IgG antibodies in Guillain–Barré syndrome. J. Neurol. Sci.195(2), 145–148 (2002).
  • Yako K, Kusunoki S, Kanazawa I. Serum antibody against a peripheral nerve myelin ganglioside, LM1, in Guillain–Barré syndrome. J. Neurol. Sci.168(2), 85–89 (1999).
  • Yuki N, Tagawa Y, Handa S. Autoantibodies to peripheral nerve glycosphingolipids SPG, SLPG, and SGPG in Guillain–Barré syndrome and chronic inflammatory demyelinating polyneuropathy. J. Neuroimmunol.70(1), 1–6 (1996).
  • Irie S, Saito T, Nakamura K et al. Association of anti-GM2 antibodies in Guillain–Barré syndrome with acute cytomegalovirus infection. J. Neuroimmunol.68(1–2), 19–26 (1996).
  • Yuki N, Tagawa Y. Acute cytomegalovirus infection and IgM anti-GM2 antibody. J. Neurol. Sci.154(1), 14–17 (1998).
  • Miyazaki T, Kusunoki S, Kaida K, Shiina M, Kanazawa I. Guillain–Barré syndrome associated with IgG monospecific to ganglioside GD1b. Neurology56(9), 1227–1229 (2001).
  • Ho TW, Mishu B, Li CY et al. Guillain–Barré syndrome in northern China: relationship to Campylobacter jejuni infection and anti-glycolipid antibodies. Brain118, 597–605 (1995).
  • Islam Z, Jacobs BC, van Belkum A et al. Axonal variant of Guillain–Barré syndrome associated with Campylobacter infection in Bangladesh. Neurology74(7), 581–587 (2010).
  • Ogawara K, Kuwabara S, Mori M, Hattori T, Koga M, Yuki N. Axonal Guillain–Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann. Neurol.48(4), 624–631 (2000).
  • Capasso M, Caporale CM, Pomilio F, Gandolfi P, Lugaresi A, Uncini A. Acute motor conduction block neuropathy: another Guillain–Barré syndrome variant. Neurology61(5), 617–622 (2003).
  • Kaida K, Sonoo M, Ogawa G et al. GM1/GalNAc-GD1a complex: a target for pure motor Guillain–Barré syndrome. Neurology71(21), 1683–1690 (2008).
  • Griffin JW, Li CY, Ho TW et al. Pathology of the motor-sensory axonal Guillain–Barré syndrome. Ann. Neurol.39(1), 17–28 (1996).
  • Yuki N, Yoshino H, Sato S, Miyatake T. Acute axonal polyneuropathy associated with anti-GM1 antibodies following Campylobacter enteritis. Neurology40(12), 1900–1902 (1990).
  • Yuki N, Yoshino H, Sato S, Shinozawa K, Miyatake T. Severe acute axonal form of Guillain–Barré syndrome associated with IgG anti-GD1a antibodies. Muscle Nerve15(8), 899–903 (1992).
  • Yuki N, Yamada M, Sato S et al. Association of IgG anti-GD1a antibody with severe Guillain–Barré syndrome. Muscle Nerve16(6), 642–647 (1993).
  • Ho TW, Willison HJ, Nachamkin I et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain–Barré syndrome. Ann. Neurol.45(2), 168–173 (1999).
  • Kusunoki S, Chiba A, Kon K et al.N-acetylgalactosaminyl GD1a is a target molecule for serum antibody in Guillain–Barré syndrome. Ann. Neurol.35(5), 570–576 (1994).
  • Ang CW, Yuki N, Jacobs BC et al. Rapidly progressive, predominantly motor Guillain–Barré syndrome with anti-GalNAc-GD1a antibodies. Neurology53(9), 2122–2127 (1999).
  • Kusunoki S, Iwamori M, Chiba A, Hitoshi S, Arita M, Kanazawa I. GM1b is a new member of antigen for serum antibody in Guillain–Barré syndrome. Neurology47(1), 237–242 (1996).
  • Yuki N, Tagawa Y, Irie F, Hirabayashi Y, Handa S. Close association of Guillain–Barré syndrome with antibodies to minor monosialogangliosides GM1b and GM1α. J. Neuroimmunol.74(1–2), 30–34 (1997).
  • Yuki N, Ang CW, Koga M et al. Clinical features and response to treatment in Guillain–Barré syndrome associated with antibodies to GM1b ganglioside. Ann. Neurol.47(3), 314–321 (2000).
  • Ogawara K, Kuwabara S, Koga M, Mori M, Yuki N, Hattori T. Anti-GM1b IgG antibody is associated with acute motor axonal neuropathy and Campylobacter jejuni infection. J. Neurol. Sci.210(1–2), 41–45 (2003).
  • Yuki N, Sato S, Miyatake T, Sugiyama K, Katagiri T, Sasaki H. Motoneuron-disease-like disorder after ganglioside therapy. Lancet337(8749), 1109–1110 (1991).
  • Illa I, Ortiz N, Gallard E, Juarez C, Grau JM, Dalakas MC. Acute axonal Guillain–Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann. Neurol.38(2), 218–224 (1995).
  • Yuki N, Taki T, Inagaki F et al. A bacterium lipopolysaccharide that elicits Guillain–Barré syndrome has a GM1 ganglioside-like structure. J. Exp. Med.178(5), 1771–1775 (1993).
  • Susuki K, Nishimoto Y, Yamada M et al. Acute motor axonal neuropathy rabbit model: immune attack on nerve root axons. Ann. Neurol.54(3), 383–388 (2003).
  • Yuki N, Yamada M, Koga M et al. Animal model of axonal Guillain–Barré syndrome induced by sensitization with GM1 ganglioside. Ann. Neurol.49(6), 712–720 (2001).
  • Yuki N, Susuki K, Koga M et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain–Barré syndrome. Proc. Natl Acad. Sci. USA101(31), 11404–11409 (2004).
  • Susuki K, Rasband MN, Tohyama K et al. Anti-GM1 antibodies cause complement-mediated disruption of sodium channel clusters in peripheral motor nerve fibers. J. Neurosci.27(15), 3956–3967 (2007).
  • Lyu RK, Tang LM, Cheng SY, Hsu WC, Chen ST. Guillain–Barré syndrome in Taiwan: a clinical study of 167 patients. J. Neurol. Neurosurg. Psychiatry63(4), 494–500 (1997).
  • Chiba A, Kusunoki S, Shimizu T, Kanazawa I. Serum IgG antibody to ganglioside GQ1b is a possible marker of Miller Fisher syndrome. Ann. Neurol.31(6), 677–679 (1992).
  • Ito M, Kuwabara S, Odaka M et al. Bickerstaff’s brainstem encephalitis and Fisher syndrome form a continuous spectrum: clinical analysis of 581 cases. J. Neurol.255(5), 674–682 (2008).
  • Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain–Barré syndrome: clinical and immunohistochemical studies. Neurology43(10), 1911–1917 (1993).
  • Willison HJ, Veitch J. Immunoglobulin subclass distribution and binding characteristics of anti-GQ1b antibodies in Miller Fisher syndrome. J. Neuroimmunol.50(2), 159–165 (1994).
  • Yuki N, Sato S, Tsuji S, Ohsawa T, Miyatake T. Frequent presence of anti-GQ1b antibody in Fisher’s syndrome. Neurology43(2), 414–417 (1993).
  • Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I. Ganglioside composition of the human cranial nerves, with special reference to pathophysiology of Miller Fisher syndrome. Brain Res.745(1–2), 32–36 (1997).
  • Liu JX, Willison HJ, Pedrosa-Domellof F. Immunolocalisation of GQ1b and related gangliosides in human extraocular neuromuscular junctions and muscle spindles. Invest. Ophthalmol. Vis. Sci.50(7), 3226–3232 (2009).
  • Koga M, Ang CW, Yuki N et al. Comparative study of preceding Campylobacter jejuni infection in Guillain–Barré syndrome in Japan and The Netherlands. J. Neurol. Neurosurg. Psychiatry70(5), 693–695 (2001).
  • Kimoto K, Koga M, Odaka M et al. Relationship of bacterial strains to clinical syndromes of Campylobacter-associated neuropathies. Neurology67(10), 1837–1843 (2006).
  • Koga M, Gilbert M, Li J et al. Antecedent infections in Fisher syndrome: a common pathogenesis of molecular mimicry. Neurology64(9), 1605–1611 (2005).
  • Houliston RS, Koga M, Li J et al. A Haemophilus influenzae strain associated with Fisher syndrome expresses a novel disialylated ganglioside mimic. Biochemistry46(27), 8164–8171 (2007).
  • Koga M, Takahashi M, Masuda M, Hirata K, Yuki N. Campylobacter gene polymorphism as a determinant of clinical features of Guillain–Barré syndrome. Neurology65(9), 1376–1381 (2005).
  • Yuki N. Acute paresis of extraocular muscles associated with IgG anti-GQ1b antibody. Ann. Neurol.39(5), 668–672 (1996).
  • Kusunoki S, Chiba A, Kanazawa I. Anti-GQ1b IgG antibody is associated with ataxia as well as ophthalmoplegia. Muscle Nerve22(8), 1071–1074 (1999).
  • Ropper AH. Unusual clinical variants and signs in Guillain–Barré syndrome. Arch. Neurol.43(11), 1150–1152 (1986).
  • Tatsumoto M, Odaka M, Hirata K, Yuki N. Isolated abducens nerve palsy as a regional variant of Guillain–Barré syndrome. J. Neurol. Sci.243(1–2), 35–38 (2006).
  • Richter RB. The ataxic form of polyradiculoneuritis (Landry–Guillain–Barré syndrome): clinical and pathologic observations. J. Neuropathol. Exp. Neurol.21, 171–184 (1962).
  • Yuki N, Susuki K, Hirata K. Ataxic Guillain–Barré syndrome with anti-GQ1b antibody: relation to Miller Fisher syndrome. Neurology54(9), 1851–1853 (2000).
  • Notturno F, Caporale CM, Uncini A. Acute sensory ataxic neuropathy with antibodies to GD1b and GQ1b gangliosides and prompt recovery. Muscle Nerve37(2), 265–268 (2008).
  • Yuki N, Susuki K, Hirata K. Ataxic form of Guillain–Barré syndrome associated with anti-GD1b IgG antibody. J. Neurol. Neurosurg. Psychiatry69(1), 136–137 (2000).
  • Kusunoki S, Shimizu J, Chiba A, Ugawa Y, Hitoshi S, Kanazawa I. Experimental sensory neuropathy induced by sensitization with ganglioside GD1b. Ann. Neurol.39(4), 424–431 (1996).
  • Takada K, Shimizu J, Kusunoki S. Apoptosis of primary sensory neurons in GD1b-induced sensory ataxic neuropathy. Exp. Neurol.209(1), 279–283 (2008).
  • Ito M, Matsuno K, Sakumoto Y, Hirata K, Yuki N. Ataxic Guillain–Barré syndrome and acute sensory ataxic neuropathy form a continuous spectrum. J. Neurol. Neurosurg. Psychiatry82(3), 294–299 (2010).
  • Bickerstaff ER, Cloake PC. Mesencephalitis and rhombencephalitis. Br. Med. J.2(4723), 77–81 (1951).
  • Yuki N, Sato S, Tsuji S, Hozumi I, Miyatake T. An immunologic abnormality common to Bickerstaff’s brain stem encephalitis and Fisher’s syndrome. J. Neurol. Sci.118(1), 83–87 (1993).
  • Nagashima T, Koga M, Odaka M, Hirata K, Yuki N. Continuous spectrum of pharyngeal–cervical–brachial variant of Guillain–Barré syndrome. Arch. Neurol.64(10), 1519–1523 (2007).
  • O’Leary CP, Veitch J, Durward WF, Thomas AM, Rees JH, Willison HJ. Acute oropharyngeal palsy is associated with antibodies to GQ1b and GT1a gangliosides. J. Neuro. Neurosurg. Psychiatry61(6), 649–651 (1996).
  • Koga M, Yoshino H, Morimatsu M, Yuki N. Anti-GT1a IgG in Guillain–Barré syndrome. J. Neurol. Neurosurg. Psychiatry72(6), 767–771 (2002).
  • Brettle RP, Gross M, Legg NJ, Lockwood M, Pallis C. Treatment of acute polyneuropathy by plasma exchange. Lancet2(8099), 1100 (1978).
  • The Guillain–Barré syndrome Study Group. Plasmapheresis and acute Guillain–Barré syndrome. Neurology35(8), 1096–1104 (1985).
  • Kuwabara S, Mori M, Ogawara K et al. Intravenous immunoglobulin therapy for Guillain–Barré syndrome with IgG anti-GM1 antibody. Muscle Nerve24(1), 54–58 (2001).
  • Jacobs BC, Schmitz PI, van der Meché FG. Campylobacter jejuni infection and treatment for Guillain–Barré Syndrome. N. Engl. J. Med.335(3), 208–209 (1996).
  • Nishimoto Y, Koga M, Kamijo M, Hirata K, Yuki N. Immunoglobulin improves a model of acute motor axonal neuropathy by preventing axonal degeneration. Neurology62(11), 1939–1944 (2004).
  • Buchwald B, Ahangari R, Weishaupt A, Toyka KV. Intravenous immunoglobulins neutralize blocking antibodies in Guillain–Barré syndrome. Ann. Neurol.51(6), 673–680 (2002).
  • Zhang G, Lopez PH, Li CY et al. Anti-ganglioside antibody-mediated neuronal cytotoxicity and its protection by intravenous immunoglobulin: implications for immune neuropathies. Brain127(Pt 5), 1085–1100 (2004).
  • Halstead SK, Zitman FM, Humphreys PD et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain131(Pt 5), 1197–1208 (2008).
  • Phongsisay V, Susuki K, Matsuno K et al. Complement inhibitor prevents disruption of sodium channel clusters in a rabbit model of Guillain–Barré syndrome. J. Neuroimmunol.205(1–2), 101–104 (2008).
  • Kaida K, Kamakura K, Ogawa G et al. GD1b-specific antibody induces ataxia in Guillain–Barré syndrome. Neurology71(3), 196–201 (2008).
  • Kaida K, Morita D, Kanzaki M et al. Anti-ganglioside complex antibodies associated with severe disability in GBS. J. Neuroimmunol.182(1–2), 212–218 (2007).
  • Kuijf ML, Godschalk PC, Gilbert M et al. Origin of ganglioside complex antibodies in Guillain–Barré syndrome. J. Neuroimmunol.188(1–2), 69–73 (2007).
  • Lopez PH, Zhang G, Bianchet MA, Schnaar RL, Sheikh KA. Structural requirements of anti-GD1a antibodies determine their target specificity. Brain131(Pt 7), 1926–1939 (2008).
  • Griffin JW, Li CY, Macko C et al. Early nodal changes in the acute motor axonal neuropathy pattern of the Guillain–Barré syndrome. J. Neurocytol.25(1), 33–51 (1996).
  • Buchwald B, Zhang G, Vogt-Eisele AK et al. Anti-ganglioside antibodies alter presynaptic release and calcium influx. Neurobiol. Dis.28(1), 113–121 (2007).
  • Lopez PH, Zhang G, Zhang J et al. Passive transfer of IgG anti-GM1 antibodies impairs peripheral nerve repair. J. Neurosci.30(28), 9533–9541 (2010).
  • Uncini A, Yuki N. Electrophysiologic and immunopathologic correlates in Guillain–Barré syndrome subtypes. Expert Rev. Neurother.9(6), 869–994 (2009).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.